Algeta Enters Research Collaboration to Evaluate Thorium

Algeta ASA (ALGETA), a Norwegian company focused on the development of novel targeted cancer therapeutics, entered a research collaboration with Genzyme to evaluate the potential of its Thorium platform.

To contact the editor responsible for this story: Meera Bhatia at mbhatia2@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.